c_Jun (Phospho_Ser73) Antibody
- Known as:
- c_Jun (Phospho_Ser73) Antibody
- Catalog number:
- E011003-2
- Product Quantity:
- 100ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- c_Jun (Phospho_Ser73) Antibody
Related products to: c_Jun (Phospho_Ser73) Antibody
Related articles to: c_Jun (Phospho_Ser73) Antibody
- Sepsis is a significant contributor to mortality for trauma patients beyond 48 hours from their initial trauma, in addition to being a major source of morbidity in the elective surgery population. Prophylactic antibiotics are recommended for patients presenting with penetrating trauma due to this risk. Current guidelines do not provide definitive recommendations on redosing for patients requiring blood transfusions. We sought to characterize the bioavailability of prophylactic antibiotics in the setting of severe hemorrhage and whole-blood resuscitation in a swine model. - Source: PubMed
Publication date: 2026/05/22
Livezey Jonathan BAnklowitz AndrewChow David RMcKinley Thomas M RWilliams TaylorRiddle LauraHorton JohnKuckelman John PAranda Marcos - Pediatric thoracolumbar spinal injuries (TLSIs) are rare and uncommonly require intervention. In adults, plain x-ray is not adequate to screen for spinal injury. In children, plain film utilization for screening is variable and supportive evidence is lacking. Liberal CT screening for TLSI in children results in significant unnecessary radiation exposure. We investigated the utility of plain x-rays and physical exam (PE) to screen children for TLSI. - Source: PubMed
Publication date: 2026/05/22
Prabhala TarunHerzog AvaScheub RachelAta AsharAdamo Matthew ABevington TravisFabiano TiffanyPierce DrewSalik IrimEdelman DanielPierson LaurenCoffey BenjaminWakeman Derek SChess MitchellWallenstein KimEdwards Mary - Per- and polyfluoroalkyl substances (PFAS) are persistent environmental pollutants associated with placenta-mediated pregnancy complications, including preeclampsia, fetal growth restriction, and preterm birth. The syncytiotrophoblast (STB), which forms the placental barrier at the maternal-fetal interface and is directly exposed to maternal blood, is a primary site of PFAS exposure. Although PFAS induce STB apoptosis, the upstream stress-signaling pathways involved remain poorly defined. Here, we investigated stress-responsive signaling mechanisms mediating PFAS-induced STB cell death. STB differentiated from human trophoblast stem cells were exposed to vehicle or an environmentally relevant mixture of five PFAS (PFOA, PFOS, PFHxS, PFNA, and PFDA; 0.0138-34.5 µM) for 3 or 6 hours. Cytotoxicity, apoptosis, mitochondrial membrane potential, and stress-signaling pathway activation were assessed by lactate dehydrogenase release, immunoblotting, JC-10 assay, and RT-qPCR. PFAS mixtures did not induce cytotoxicity at 3 hours but significantly increased cytotoxicity at 6 hours at 34.5 µM, coinciding with induction of cleaved caspase-3, cleaved PARP, and NOXA. The pan-caspase inhibitor z-VAD-FMK prevented cytotoxicity, indicating caspase-dependent apoptosis. PFAS exposure reduced mitochondrial membrane potential and activated the integrated stress response (ISR), as evidenced by eIF2α phosphorylation, ATF4 induction, and increased ATF4 target gene expression. In parallel, c-Jun N-terminal kinase (JNK) signaling was activated, as evidenced by JNK phosphorylation and induction of immediate-early genes (JUN, FOS, EGR1). Pharmacologic inhibition of the ISR modestly attenuated PFAS-induced cytotoxicity, whereas pharmacologic inhibition of JNK rescued cytotoxicity and apoptotic signaling. Together, these findings identify JNK-driven stress signaling as the dominant mediator of PFAS-induced STB apoptosis, with a secondary contribution from the ISR. - Source: PubMed
Publication date: 2026/05/22
Kozai KeisukeVarberg Kaela M - In low- and middle-income countries (LMICs), resources for cancer care are limited and access to quality cancer care can be difficult. Access to cancer care is also limited in rural areas of developed countries. The increasing cancer burden in LMICs and persistent care disparities in rural areas require practical approaches for improving access to quality cancer care in underserved areas. This study reviews lessons learned from ASCO initiatives to provide quality cancer care to LMICs and the rural United States using Quality Oncology Practice Initiative-based frameworks. These efforts demonstrate the feasibility of providing quality cancer care in resource-limited settings. A summary of these findings is provided, including recommendations for overcoming barriers to successful implementation that are broadly applicable across diverse clinical settings. - Source: PubMed
Publication date: 2026/05/22
Jazieh Abdul-RahmanBogere NaghibUmanzor Funez Gerardo AntonioHensold Jack O - Ovarian cancer is the most lethal gynecologic malignancy in the United States, with more than 20,000 new cases and 12,730 deaths estimated in 2025. Surgical cytoreduction and platinum-based chemotherapy are critical in the management of advanced ovarian cancer. Decisions regarding timing of surgery are complex and must factor in the both the distribution of disease (dictating the likelihood of complete resection and radicality required to achieve this) and the fitness of the patient. Here, we review the landmark studies evaluating surgical timing in patients with advanced ovarian cancer (primary cytoreductive surgery versus interval cytoreductive surgery after neoadjuvant chemotherapy) and highlight the current limitations of the data. While questions remain, complete cytoreduction at the time of surgery confers optimal oncologic outcomes and should be prioritized regardless of the timing of surgery. - Source: PubMed
Publication date: 2026/05/22
Bixel KristinOlawaiye AlexanderFlanigan MargaretHaight PaulinaMahner SvenFotopoulou Christina